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Abstract 
Background: Abnormalities of endothelial cell function are proposed to be a critical factor underlying adverse 
cardiovascular outcomes in the setting of hyperglycaemia. While high‑density lipoproteins (HDL) have been demon‑
strated to be cardioprotective, the impact on the endothelium in hyperglycaemia has not been fully elucidated.
Methods: Human umbilical vein endothelial cells (HUVECs) were exposed to high‑glucose conditions using dex‑
trose, the main isoform of glucose, and native HDL. HUVEC proliferation and migration were determined. The key 
signalling pathways that regulate endothelial cell function were also characterized.
Results: Increasing concentrations of dextrose resulted in significant reductions in HUVEC proliferation, this was 
attenuated by coincubation with HDL. In support of this, HDL was also found to rescue dextrose impaired expres‑
sion of PCNA and the activation (phosphorylation) of the key transcription factor for proliferation ERK. Dextrose also 
dose‑dependently inhibited HUVEC migration, which was mitigated by co‑incubation with HDL. Consistent with this, 
HDL prevented dextrose‑induced inhibition of p38 phosphorylation, responsible for cell migration. Finally, phospho‑
rylation of the pro‑survival transcription factor Akt was dose‑dependently inhibited by dextrose, however, this was 
completely rescued by co‑administration with HDL.
Conclusion: Dextrose‑induced hyperglycaemia causes the impairment of endothelial cell proliferation and migration 
and inhibits the activation of ERK, p38 and Akt pathways. The protective effects of HDL in this milieu highlights the 
potential for HDL to improve vascular repair in patients with impaired glucose homeostasis.
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Introduction
Uncontrolled hyperglycaemia has long been recognized 
as a major risk factor in the development of vascular com-
plications in diabetic patients [1]. Diabetic macrovascu-
lar complications are involved in ischemic heart disease 
[2], peripheral vascular disease [3] and thromboembolic 
stroke [4]. These complications are major contributors to 
the morbidity and mortality associated with diabetes [5]. 
Another important diabetic feature are vascular lesions 
which involves impaired endothelial-dependent vasomo-
tor responses and significant alterations in endothelial 
growth, survival and migration induced by exposure of 
vascular endothelial cells to high glucose [6–8]. A causal 
link between diabetic hyperglycaemia and the develop-
ment of macrovascular complications has been estab-
lished early in the disease onset and tight glucose control 
in diabetic patients have been shown to reduce the pro-
gression of disease [9].
Endothelial cells play critical roles in vascular biology, 
being both the protective inner lining of vessels and the 
local site for oxygen delivery to all tissues. Endothelial 
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damage or dysfunction is considered a critical initiator of 
large vessel diseases such as atherosclerosis [8]. An intact 
endothelial cell monolayer modulates local haemostasis 
and thrombolysis and provides a non-permeable bar-
rier protecting vascular smooth muscle cells (VSMCs) 
from circulating growth-promoting factors [10]. Vascular 
endothelial cell proliferation and migration are vital in 
many physiological and pathological processes, such as 
angiogenesis and healing of the injured endothelium [11].
It has been shown in previous investigations that high 
glucose exposure in human umbilical vein cells (HUVEC) 
impairs endothelial function such as insulin signal-
ling [12] and expression of a host of proteins involved 
in thrombosis and blood viscosity [13]. A number of 
in  vitro studies focused on the effects of high glucose 
concentration on growth and survival of various types of 
endothelial cells (EC), including HUVECs [7, 14], human 
pulmonary artery EC [15], human dermal microvascular 
EC [16], aortic EC [17] and retinal EC [18, 19]. However, 
conflicting results in EC properties under high glucose 
[20, 21] make the interpretation of these results difficult. 
These conflicting reports may be explained by differences 
in species, macrovascular ECs versus microvascular ECs, 
or changes in experimental conditions, but most likely 
reflects fundamental differences in EC cell type.
Epidemiological studies show that high-density lipo-
protein (HDL) is antiatherogenic and an independent 
protective factor for coronary artery diseases [22]. HDL 
and its major protein constituent apolipoprotein A-1 
(apoA-1) play major roles in mediating reverse choles-
terol transport (RCT), an important atheroprotective 
mechanism. HDL has many other functions, including 
removal or detoxification of oxidized sterols/phospholip-
ids and its anti-inflammatory, antioxidant and antithrom-
botic activities [23–25]. HDL also exhibits potent 
endothelial protective and reparative capabilities [10, 24]. 
HDL has been shown to promote endothelial cell migra-
tion and protect it from cellular apoptosis as well as ele-
vate nitric oxide (NO) production through increases in 
endothelial NO synthase (eNOS) expression and activity 
[10, 26]. However, the efficiency of HDL on high glucose-
triggered dysfunction in ECs and the related signalling 
pathways is still to be fully elucidated.
The present study aimed to determine if HDL can 
attenuate dextrose-induced high glucose impaired 
HUVEC proliferation and migration as well as the acti-
vation of the key transcription factors ERK, p38 and 
Akt that regulate these functions. We used dextrose as 
this is the most common, naturally occurring isoform of 
glucose. We report that dextrose inhibits EC migration, 
proliferation and the phosphorylation of ERK, p38 and 
Akt. Coincubation with HDL completely mitigates these 
effects. Our findings provide a greater understanding of 
the endothelial protective effects of HDL, with implica-
tions for the treatment of diabetic vascular complications.
Materials and methods
Cell isolation, culture and preparation of HDL
HUVECs (Cell Applications Inc., San Diego, CA, USA) 
were maintained in MCDB (Molecular, Cellular, and 
Developmental Biology) medium containing 15% fetal 
bovine serum (FBS, lipoprotein deficient), 0.009% heparin, 
0.015% endothelial cell growth supplement (Cat. Number 
E0760; Sigma, St. Louis, MO, USA) and used between 
passage 3 and 6 [10]. HDL (1.063  <  d  <  1.21  g/mL) was 
isolated by sequential ultracentrifugation from human 
plasma as previously described [27]. Briefly, the density 
of human plasma was modified with potassium bromide 
(Sigma, St. Louis, MO, USA) to the desired density and 
sequentially ultracentrifuged in a Beckmann 50.2 Ti rotor 
(Beckmann Coulter, Brea, CA, USA) at 50,000  rpm at 
4 °C. The HDL fraction was dialysed against 3 × 1 L PBS, 
filtered-sterilised (0.22 µm) and stored in a light-excluding 
container at 4  °C under nitrogen gas. HDL protein was 
measured using a Bio-Rad protein assay (Bio-Rad, Rich-
mond, CA, USA) and added to the HUVECs on the basis 
on total HDL protein concentration (µg/mL).
Cell proliferation assay
Proliferation assays were performed in plates coated 
with collagen II (Cat. Number C9301; Sigma, St. Louis, 
MO, USA). Briefly, HUVECs were serum-deprived for 
24 h (0.5% FBS) before the cells were exposed to increas-
ing dextrose concentrations (5.7–40  mM; Cat. Num-
ber G7528; Sigma, St. Louis, MO, USA) and/or HDL 
(5–120  μg/mL total protein concentration) in a back-
ground media with 2.5% FBS. Cell proliferation was 
measured after a 96 h incubation as cell number using a 
bromodeoxyuridine (BrdU) incorporation assay (BrdU 
kit; Millipore, Temecula CA, USA). Total cellular protein 
content in 6-well plates was determined from cell lysates 
with the Bio-Rad protein assay (Bio-Rad, Richmond, CA, 
USA) [7]. The experiments were performed in triplicate 
and repeated at least 3 times.
Boyden chamber migration assay
A migration assay was performed using transwells (8 µm 
pore polycarbonate membrane, 24 well, Costar, Sigma, 
St. Louis, MO, USA) [10, 28]. Briefly, after HUVECs were 
seeded on the upper chamber, they were firstly serum-
deprived for 12  h (0.5% FBS) then the transwells were 
placed into the lower chamber containing increasing dex-
trose concentrations (5.7–40  mM) and/or HDL (80  μg/
mL in total protein concentration) in a background 
media of 2.5% FBS and incubated overnight. The cells 
that migrated to the underside of the membrane were 
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fixed and the membranes were mounted on slides using 
mounting medium with DAPI (Vector Laboratories, 
Burlingame, CA, USA.). The number of migrated cells 
was determined from microscopic images of transwell 
membranes. The experiments were performed in tripli-
cate and repeated at least 3 times.
Western blotting
HUVECs were seeded in 6-well plates for 48 h in MCDB 
medium containing 15% FBS, after which the cells were 
serum-starved (0.5% FBS in MCDB) for 24  h. The cells 
were then incubated with dextrose or HDL (2.5% FBS 
background media) at the indicated concentrations for 
either: 72 h (PCNA), 5 min (pAkt/Akt) or 15 min (p-p38/
p38 and pERK/ERK). Cells were lysed, sonicated and sub-
jected to standard Western blotting methods [10, 29]. 
The individual primary antibodies used were anti-PCNA 
(1:2000 dilution), anti-Akt/anti-pAkt (residue Ser-473, 
1:1000), anti-ERK/anti-p-ERK1/2 (1:2000) and anti-p-
p38/anti-p38 (1:1000) (Cell Signaling, Beverly, MA). Equal 
protein loading was verified by stripping membranes of 
original antibodies and re-probing with the primary anti-
body anti-β-actin (1:3000; Cell Signaling, Beverly, MA). 
Protein levels were quantified from digitized images using 
ImageLab (Bio-Rad, Richmond, CA, USA). The inhibitors 
PD98059 (ERK1/2 inhibition; 6.0  µM; Sigma, St. Louis, 
MO, USA), SB203580 (p38 inhibition; 50 µM; Sigma, St. 
Louis, MO, USA) and LY294002 (Akt inhibition; 20 µM: 
Sigma, St. Louis, MO, USA) were dissolved in DSMO 
(dimethyl sulfoxide; Sigma, St. Louis, MO, USA) and were 
used to identify the pathway of cellular activation.
Data analysis
Data are expressed as mean ± SEM unless stated oth-
erwise. Means of 2 groups were compared using Stu-
dent’s t test (unpaired, 2-tailed), and one-way ANOVA 
was used for comparison of more than 2 groups, with 
p < 0.05 considered to be statistically significant. These 
results were tested for normality and equality of vari-
ances. For those results that did not satisfied those 
criteria, non-parametric Wilcoxon or Welch t test 
were used. Unless indicated in the figure legends, all 
the experiments were performed at least 3 times in 
triplicate.
Results
HDL attenuates dextrose‑induced inhibition of HUVEC 
proliferation
Treatment of HUVECs with dextrose resulted in a sig-
nificant concentration-dependent decrease in BrdU 
proliferation (22.1 ±  5.1% at 20  mM and 36.5 ±  6.1% at 
40 mM, Fig. 1a), compared to the normo-glucose control 
(5.7  mM dextrose). This inhibition of proliferation was 
reversed when HDL (80  µg/mL) was co-incubated with 
dextrose, increasing proliferation when compared to dex-
trose only control cells at each concentration (24.3 ± 7.6 
and 33.5 ±  5.9% at 20 and 40 mM dextrose respectively, 
Fig.  1a). Consistent with the proliferation findings, dex-
trose-induced high glucose caused dose dependent reduc-
tions in PCNA (proliferating cell nuclear antigen) protein 
levels. Co-incubation with HDL, however, was able to 
























































Fig. 1 HDL attenuates dextrose‑induced inhibition of HUVEC proliferation. a Cell proliferation was determined after cells were incubated with 
dextrose (5.7, 20 and 40 mM) or dextrose plus HDL (80 µg/mL) for 96 h using BrdU incorporation. 2.5% FBS (control) and 15% FBS (positive control) 
treatments were also included. b Protein levels of PCNA were determined in HUVEC lysates incubated with dextrose (5.7, 20 and 40 mM) or dextrose 
plus HDL (80 µg/mL) for 72 h using Western blotting. β‑Actin was used as the protein loading control. Data shown are the mean ± SEM of results 
from three independent experiments. #p < 0.05 relative to the respective control (cells in MCDB medium containing 2.5% FBS). *p < 0.05 relative to 
the dextrose only treatments at the same concentration
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HDL attenuates dextrose‑induced inhibition of ERK 
activation
Changes in the activation of ERK1/2, a key signalling 
protein for the induction of proliferation, following incu-
bation with dextrose and HDL were next investigated. 
Dextrose (5.7–60 mM) inhibited the phosphorylation of 
ERK1/2 in a step-wise manner (Fig.  2a). Suppression of 
ERK1/2 activation by dextrose (20 mM) was completely 
reversed with the co-incubation of HDL (5–120  µg/
mL). ERK1/2 phosphorylation was significantly elevated 
above normo-glucose control levels at HDL concentra-
tion of 10  µg/mL, with maximal ERK1/2 phosphoryla-
tion (~  fourfold) observed at 120 µg/mL HDL (Fig.  2b). 
It was found that HDL (80  µg/mL) was able to over-
come dextrose-induced inhibition of ERK1/2 activation 
with higher doses of dextrose (up to 40 mM, Fig. 2c). To 
confirm the specific induction of ERK1/2 activation by 
HDL in the presence of dextrose, the effects of ERK1/2 
inhibitor, PD98059, were assessed. Co-incubation with 
PD98059 completely abrogated FBS, HDL and dex-
trose  +  HDL—induced ERK1/2 phosphorylation, con-
firming the involvement of HDL in this pathway (Fig. 2d).
HDL rescues dextrose‑induced inhibition of HUVEC 
migration
Dextrose-induced high glucose inhibited HUVEC migra-
tion in a concentration dependent manner, with a decrease 
in HUVEC migration of 23.6  ±  5.7 and 38.7  ±  7.1% at 
dextrose concentrations of 20 and 40  mM respectively. 
Co-incubation with HDL (80 µg/mL) was able to reverse 
this inhibition and caused increases in HUVEC migration, 
compared to dextrose only controls at the respective con-
centrations (21.7 ± 2.3, 55.5 ± 6.5 and 60.8 ± 3.3% at 5.7, 
20 and 40 mM dextrose respectively, Fig. 3).
HDL attenuates dextrose‑induced inhibition of p38 
activation
Changes in the activation of p38, a critical promoter of 
cell migration, was next assessed. Dextrose (5.7–60 mM) 
inhibited the phosphorylation of p38 in a dose-dependent 
manner (Fig. 4a). In the presence of 20 mM dextrose, co-
incubation with HDL at a concentration as low as 10 µg/
mL was able to activation p38 phosphorylation above the 
normo-glucose control, with maximal p38 phosphoryla-
tion (~  5.5-fold) observed at 120  µg/mL HDL (Fig.  4b). 
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Fig. 2 HDL attenuates dextrose‑induced inhibition of ERK activation. HUVECs were incubated with increasing dextrose concentrations (5.7–60 mM) 
for 15 min (a), or HDL (5–120 µg/mL) (b), *p < 0.05, **p < 0.01 relative to dextrose alone (5.7 mM). Incubation of HDL (80 µg/mL) with increasing 
dextrose (5.7, 20 and 40 mM) in a background media of 2.5% MCDB, *p < 0.05, **p < 0.01 compared to relative dextrose concentration alone (c). 
HDL (80 µg/mL) with either dextrose (20 mM) and/or ERK inhibitor (PD98059) for 1 h (d). ERK phosphorylation was determined by Western blot 
analysis. Data is expressed as a ratio of p‑ERK to total‑ERK. *p < 0.05 relative to the PD98059 treatment. Data shown are representative of results from 
3 independent experiments
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HDL (80  µg/mL) was also able to increase p38 phos-
phorylation in higher concentrations of dextrose (up 
to 40  mM, Fig.  4c). Finally, to confirm the activation of 
p38 by HDL, a specific inhibitor of p38, SB203580, was 
included. It was found that incubation with SB203580 
attenuated FBS, HDL and dextrose + HDL-induced p38 
phosphorylation, confirming the role of HDL in the acti-
vation of this pathway.
HDL mitigates the inhibition of Akt phosphorylation 
by dextrose
Increasing concentrations of dextrose caused a step-wise 
reduction in Akt phosphorylation (Fig.  5a), when com-
pared to the normo-glucose control. In the presence of 
dextrose (20 mM), HDL was able to significantly increase 
the phosphorylation of Akt that reached significance 
at the 10  µg/mL concentration and increased further at 
20  µg/mL, followed by a plateau, but remained signifi-
cantly elevated up to 120  µg/mL, compared to dextrose 
(20  mM) only control cells (Fig.  5b). Furthermore, co-
incubation of dextrose with HDL (80  µg/mL) was able 
to rescue high glucose-impaired Akt phosphorylation at 
dextrose concentrations up to 40 mM (Fig. 5c). A specific 
inhibitor of Akt, LY294002, was used to confirm that acti-
vation of this pathway by HDL. Inclusion of LY294002 
was found to completely prevent HDL-induced activa-
tion of Akt phosphorylation (Fig. 5d).
Discussion
We report that HDL is able to attenuate high glucose-
impaired endothelial cell function and signalling. 
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Fig. 3 HDL rescues dextrose‑induced inhibition of HUVEC migration. HUVEC migration was determined using transwell membranes. HUVECs were 
seeded on the upper chamber, serum‑deprived for 12 h, then the transwells were placed into the lower chamber containing increasing dextrose 
concentrations (5.7–40 mM) and/or HDL (80 μg/mL) and incubated overnight. The cells that migrated through the membrane were fixed and 
stained by DAPI. Upper panels are representative images of membranes of migrated cells. Data shown are the mean ± SEM of results performed in 
triplicate from 3 independent experiments. #p < 0.05 relative to the control (2.5% FBS treatment). *p < 0.05 compared to relative dextrose concen‑
tration alone
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significantly suppresses the important endothelial func-
tions of proliferation and migration, as well as the related 
ERK, p38 and Akt signalling pathways. Coincubation 
with HDL is able rescue these impairments to normo-
glucose levels. These findings have implications for the 
therapeutic modulation of endothelial repair by HDL in 
diabetes.
The cardio-protective role of HDL has been observed 
for decades [22–25], but there are gaps in knowledge 
regarding its effect on HUVEC proliferative and the 
related cell signalling pathway in the settling of early high 
glucose insult. The protein kinase Akt is a multifunc-
tional regulator of cell growth and survival [30, 31]. Akt 
is primarily activated when the threonine 308  (Thr308) 
and serine 473  (Ser473) residues are phosphorylated by 
PI3-K, which in turn then activate Akt serine/threonine 
kinase activity. In this study, the level of phosphorylated 
Akt at  Ser473 was significantly inhibited by dextrose-
induced high glucose, but rescued by coincubation with 
HDL. Pre-treatment of HUVECs with the Akt inhibitor 
LY294002 almost completely inhibited HDL-induced Akt 
phosphorylation providing further evidence that this is 
mediated by Akt. These findings are consistent with other 
studies that have found reconstituted HDL (rHDL) aug-
ments Akt phosphorylation [26]. In the early stages of a 
high glucose insult, suppression of the activation of Akt 
likely plays an important role in the impairment of cell 
survival [32]. It has been shown that hyperglycaemic 
exposure results in decreased viability and attenuated 
proliferation of endothelial cells and this is the result of 
downregulation of platelet-derived growth factor C and 
its receptor [33]. The activation of Akt is downstream of 
this axis. Therefore, the maintenance of Akt by HDL in 
high glucose suggests HDL may play a role in improved 
endothelial integrity in hyperglycaemia. This concept is 
consistent with previous studies [6, 34].
The processes of endothelial cell proliferation and 
migration are crucial to both neovascularisation and 
a successful response to vascular injury [9]. High glu-
cose induced endothelial dysfunction is known to not 
only involve impaired endothelial cell proliferation but 
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Fig. 4 HDL attenuates dextrose‑induced inhibition of p38 activation. HUVECs were incubated with increasing dextrose concentrations (5.7–60 mM) 
for 15 min (a) or HDL (5–120 µg/mL) (b), *p < 0.05, relative to dextrose alone (5.7 mM). Incubation of HDL (80 µg/mL) with increasing dextrose 
(5.7, 20 and 40 mM), *p < 0.05, **p < 0.01 compared to relative dextrose concentration alone (c). HDL (80 µg/mL) with either dextrose (20 mM) 
and/or p38 inhibitor (SB203580) for 1 h (d). p38 phosphorylation was determined by Western blot analysis. Data is expressed as a ratio of p‑p38 to 
total‑p38. *p < 0.05 relative to the SB203580 treatment. Background media was 2.5% FBS MCDB. Data shown are representative of results from 3 
independent experiments
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promote endothelial cell proliferation and migration in 
response to various extracellular stimuli [35]. Major sub-
families of structurally related MAPKs have been identi-
fied in mammalian cells, including ERK1/2 MAPK, p38 
MAPK and c-Jun N-terminal kinase/stress-activated 
protein kinase (JNK/SAPKs) [11]. It has been shown 
that HDL-stimulated endothelial cell migration is driven 
by the activation of Src kinase, PI3K-kinase and p44/42 
MAP kinase [26]. The current study now shows that HDL 
rescues the high-glucose-impaired HUVECs migration. 
Consistent with this we found that HDL reversed the 
inhibition of p-38 activation in high glucose, a key tran-
scription factor for the promotion of cell migration. The 
use of a specific p38 inhibitor in this study attenuated the 
induction of p-p38 by HDL in high glucose, confirming 
the importance of its role. These results demonstrate a 
role for HDL in the rescue of high glucose-impaired cell 
migration and proliferation. In support of our findings, a 
recent study [36] found rHDL was able to restore angio-
genesis in a diabetic murine model of hind limb ischemia. 
This was shown in vitro to be mediated by the scavenger 
receptor (SR-BI) which led to the activation of the PI3 K/
Akt signalling pathway. On the flip side, dysfunctional 
HDL isolated from diabetic patients, has diminished 
capacity to stimulate HUVECs proliferation and migra-
tion [37]. These investigators showed that dysfunctional 
HDL induced Akt phosphorylation initially but this was 
attenuated with time as SR-BI was down regulated by the 
dysfunctional lipoprotein. Glycated HDL was also shown 
to attenuate NO production and increase reactive oxy-
gen/nitrogen species in human aortic endothelial cells 
[38]. Other properties of HDL were also compromised 
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Fig. 5 HDL mitigates the inhibition of Akt phosphorylation by dextrose. HUVECs were incubated with increasing dextrose concentrations 
(5.7–60 mM) for 15 min (a) or HDL (5–120 µg/mL) (b), *p < 0.05, **p < 0.01 relative to dextrose alone (5.7 mM). Incubation of HDL (80 µg/mL) with 
increasing dextrose (5.7, 20 and 40 mM), *p < 0.05, **p < 0.01 compared to relative dextrose concentration alone (c). HDL (80 µg/mL) with either 
dextrose (20 mM) and/or pAkt inhibitor (LY294002) for 1 h (d). Akt phosphorylation was determined by Western blot analysis. Data is expressed as a 
ratio of p‑Akt to total‑Akt. *p < 0.05 relative to the LY294002 treatment. Data shown are representative of results from 3 independent experiments
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Clinical studies using infusions of reconstituted HDL 
(rHDL, apoA-1  +  phospholipid) have already dem-
onstrated promising findings in diabetic patients. For 
example, a single infusion of rHDL into type 2 diabetes 
mellitus (T2DM) patients was found to reduce platelet 
activation [40]. Other studies have found that rHDL infu-
sions in T2DM patients elevate circulating endothelial 
progenitor cell number [41] and increase the anti-inflam-
matory properties of endogenous HDL [42]. These stud-
ies report that the kinetics of an rHDL infusion are such 
that there is a steady increase in circulating HDL-choles-
terol (50%) and apoA-1 concentrations (> twofold) during 
the 4 h infusion period. Then out to 72 h post-infusion, 
the concentration of apoA-1 drops by ~  50% while the 
HDL-cholesterol remains elevated. These studies sug-
gest that in the context of diabetes, infusions of rHDL are 
likely to provide beneficial effects on the endothelium. 
Whilst the half-life of apoA-1 and HDL-cholesterol may 
be viewed as relatively short, it must sufficient to impart 
significant changes during that time.
This interaction between HDL, SR-BI, endothelial 
function and its signalling pathways may have important 
implications not only in CVD but also in cancer [43]. 
Depending on the cancer type, SR-BI expression can cor-
relate with survival rates. SR-BI activation by HDL play 
a critical role in signalling that stimulates endothelial 
cell proliferation and migration, important for tumour 
growth. HDL have been shown to activate Akt and 
ERK1/2 pathways in breast cancer while knockdown 
and pharmacological inhibition of SR-BI resulted in a 
decrease in these pathways [44].
In conclusion, we show that HDL protects endothe-
lial cells from high glucose-impaired cell proliferation 
and migration. Additionally, HDL rescues high glucose-
impaired activation of ERK, p38 and Akt signalling path-
ways. These findings with HDL suggest that it could 
be considered as a future therapeutic target to protect 
against diabetic vascular complications.
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